HIV and TB Treatment: Two Drug Combination Study
Part of Infections clinical trials.
This study compares two different HIV medication regimens in people who have both HIV and active tuberculosis (TB) and are starting HIV treatment for the first time. The goal is to see which combination works better and is safer when taken together with TB medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–65 years old
- Body weight at least 40 kg with BMI between 18.5–30 kg/m²
- Never taken HIV medications before (treatment-naïve)
- Have active TB infection and currently taking TB medications with rifampicin and isoniazid
- CD4 count (immune cells) of at least 25 cells/μL
- HIV viral load (amount of virus) below 500,000 copies/mL
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug HIV treatment (dolutegravir and lamivudine) for people who also have active TB and are taking a standard TB medicine called rifampin. It is designed for those who have not yet started HIV treatment.
This study tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug regimen in men whose HIV is already well-controlled. If effective, this could mean taking fewer medications.
This Phase 2 study tests how well and how safely an HIV medicine (dolutegravir) works when given with rifampicin, a common anti-TB medicine, for people starting HIV treatment during TB treatment. It also studies drug levels in the body to help confirm dosing and safety while treating both infections.
This study tests a newer HIV medication, B/F/TAF, as a first-line treatment. It compares B/F/TAF with older combinations (TDF+3TC+EFV or DTG/3TC) to see how well it works for people who have never taken HIV meds.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.